Publications by authors named "Kerry Morris"
Renal cell carcinomas (RCCs) harboring the t(6;11)(p21;q12) translocation were first described in 2001 and recently recognized by the 2013 International Society of Urological Pathology Vancouver Classification of Renal Neoplasia. Although these RCCs are known to label for melanocytic markers HMB45 and Melan A and the cysteine protease cathepsin K by immunohistochemistry (IHC), a comprehensive IHC profile has not been reported. We report 10 new t(6;11) RCCs, all confirmed by break-apart TFEB fluorescence in situ hybridization.
View Article and Find Full Text PDFArticle Synopsis
- Xp11 translocation renal cell carcinomas (RCCs) are identified by specific chromosome translocations that lead to gene fusions involving the TFE3 transcription factor; diagnosis can be complicated by variable fixation in samples used for testing.
- A study reviewed 95 renal tumor cases, finding TFE3 gene rearrangements in 31 patients, with ages ranging from 6 to 67 (mean=30 years), and highlighted various distinctive features that can mimic other tumor types.
- The research demonstrated that TFE3 break-apart FISH assays are highly effective for confirming the diagnosis of Xp11 translocation RCC, even in cases with unclear TFE3 immunohistochemistry results
A subset of renal cell carcinomas (RCCs) is characterized by t(6;11)(p21;q12), which results in fusion of the untranslated Alpha (MALAT1) gene to the TFEB gene. Only 21 genetically confirmed cases of t(6;11) RCCs have been reported. This neoplasm typically demonstrates a distinctive biphasic morphology, comprising larger epithelioid cells and smaller cells clustered around basement membrane material; however, the full spectrum of its morphologic appearances is not known.
View Article and Find Full Text PDF